Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Medical Minute: Emerging Therapies and Novel Combinations for Melanoma Treatment
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: March 19, 2021 Expiration: March 18, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation
Evan J. Lipson, MD
person default
Megan Schollenberger, MSN, CRNP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate emerging data with novel investigational targeted and immunotherapeutic approaches to aid in clinical trial participation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Evan J. Lipson, MD

Associate Professor
Department of Medical Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, MacroGenics, Merck, Novartis, Odonate, Regeneron, and Sanofi; and funds for research support from Bristol-Myers Squibb, Merck, and Regeneron.
Megan Schollenberger, MSN, CRNP

Nurse Practitioner
Melanoma and Cancer Immunology Programs
Johns Hopkins University School of Medicine
Johns Hopkins Hospital
Baltimore, Maryland

Megan Schollenberger, MSN, CRNP, has no relevant conflicts of interest to report.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to disclose.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to disclose.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no relevant conflicts of interest to disclose.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, dermatologists, advanced practitioners, nurses, pharmacists, and other healthcare providers involved in the care of patients with melanoma.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with melanoma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-061-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 19, 2021, through March 18, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Medical Minute: Emerging Therapies and Novel Combinations for Melanoma Treatment
  • CME
  • CE

Loading...
In this concise interactive module, learn from experts about emerging therapeutic regimens for advanced melanoma, including tumor-infiltrating lymphocytes, intratumorally administered agents, and targeted therapy combinations.
Evan J. Lipson, MD
person default
Megan Schollenberger, MSN, CRNP
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: March 19, 2021 Expiration: March 18, 2022

Related Content

Part 2 of KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in high-risk stage III melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

5-year update of the COLUMBUS trial of encorafenib + binimetinib in BRAF V600-mutant melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

ABC study of nivolumab plus ipilimumab update at 5 years in patients with melanoma brain metastases from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

LEAP 004 trial update on lenvatinib + pembrolizumab in patients with advanced melanoma and progression on anti-PD-1/PD-L1 therapy from ASCO 2021 reported by Clinical Care Options (CCO)

Released: June 9, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue